Currently available data on drug coated balloon (DCB) angioplasty as a clinical treatment modality for coronary
and peripheral artery disease are limited but hold promise. Advantages over standard angioplasty and stent technologies
include a homogeneous drug delivery to the vessel wall, an immediate drug release without the use of a polymer, the
option of using balloon catheters alone or in combination with a bare metal stent, no foreign object left behind in the body,
the potential of reducing anti-platelet therapy, and a lower restenosis rates in some indications. The clinical and angiographic
presentation of patients with acute coronary syndromre (ACS) is heterogeneous. Therefore, different clinical
scenarios of DCB application in ACS may be discussed. Frequently, thrombosis in the ACS-related lesion plays a major
role. Patients in hemodynamic critical situations under catecholamine therapy may present with too small vessel diameters.
Another clinically relevant scenario represents in-stent restenosis (ISR) which is frequently associated with ACS.
Keywords: Drug coated balloon, acute coronary syndrome, thrombus containing lesion, angioplasty, coronary artery disease, thrombosis, stent, restenosis, chronic inflammation, myocardial infarction
Rights & PermissionsPrintExport